GLPGF - Gilead Sciences' Next Chapter - In A Coronavirus Based World Gilead Sciences' Antiviral Strength Is Key
Gilead Sciences (NASDAQ: GILD) is an $80 billion American biotechnology company that researches, develops, and commercializes drugs. The company is renowned for curing Hepatitis C and its leading HIV treatments. As we’ll see throughout this article, Gilead Sciences’ impressive portfolio, pipeline, and financials as it moves into its next chapter make it a strong investment.
Gilead Sciences - MedCity News
Gilead Sciences Next Chapter
Gilead Sciences has recently made the news due to its drugs being used as an experimental treatment for 2019-nCoV. 2019-nCoV is one of the largest novel outbreaks and will continue